To evaluate the possible use of mutant ras as a biomarker for lung cancer, we have analyzed "normal appearing" lung tissue, lung tumor, lung metastases and sputum samples from patients with non-small cell lung cancer (NSCLC). As a control, we used lung tissue and sputum samples from patients without oncological diseases or lung disorders. Our analyses were performed with the aid of enriched PCR (EPCR), a method which enables detection of ras mutation even if present at low incidence. EPCR identified K-ras codon 12 mutations in 10% of lung tissues obtained from patients with no lung diseases, whereas the same mutation was detected in 60% of samples of normal appearing lung tissues obtained from patients with NSCLC, 62% of NSCLC tumors and 80% of metastases. Analysis of sputum samples of patients with NSCLC identified 47% to harbor mutant ras allele, whereas 12.5% of controls diagnosed with non-oncological lung diseases carried this mutation. Most of these mutations were detected with the aid of EPCR only, indicating that a minority of cells in a given sample harbor this mutation. The ability to detect K-ras codon 12 mutation in 60% of lung tissue samples and in 47% of sputum samples taken from patients with lung cancer (as compared with 10% and 12.5% of respective controls) points to the potential use of ras mutation as a biomarker for exposure and possible identification of patients who may be at higher risk of developing lung cancer.

The restriction fragment length polymorphism of c-Ha-ras-1 and L-myc genes and expression of cell surface effector molecules were studied to determine their potential utility as markers for assessing risk of metastasis in 84 lung cancer patients. We performed a comparative study of primary lung carcinomas, metastases, adjacent tissues and blood samples in a group of patients with lung cancer of different histological types, grade of differentiation and presence of regional and distant metastasis. No differences in the frequency of c-Ha-ras-1 rare alleles were found between lung cancer patients and unaffected controls. The detection of common a4-allele seems to be associated with metastasis and low differentiation of lung carcinomas. S-allele of L-myc was observed in 82.6% of patients with metastatic lesions. Homozygosity of L-allele patients was not evidence for distant metastasis and only 17.4% of these patients have metastatic lesions of the lymph nodes. The expression of HLA class I and receptor of transferrin (TrRec) were tested immunohistochemically in the same patients. In the group of squamous cell carcinomas with regional metastases the expression of HLA class I antigens was decreased [7/21 (33.3%) positive staining tumors versus 13/20 (65.0%) in the group without metastases]. The opposite situation was observed for TrRec. The data of restriction fragment length polymorphism of oncogenes and expression of two cell surface effector molecules, identified in the same patients, were combined. The registration of more than one poor marker, tested in individuals with squamous cell carcinoma, closely correlated with dissemination and advanced stage of the disease. Nearly 90% (20/22) of patients with well and moderately differentiated tumor revealed metastatic lesions versus 6.6% (1/15) of patients with manifestation of a single poor marker. Finally, proposals could be made for the development of a risk group that incorporates both clinical and molecular biology features in the prediction of metastasis.

The metabolism of 14C-arachidonic acid in cell-free homogenates of 65 primary, primary multiple, and metastatic tumors of human lungs is studied. The biosynthesis of arachidonic acid lipoxygenase metabolites 12-and 15-hydroxyeicosatetraenic acids is suppressed in 9 all metastatic tumors.Key Words: primary and metastatic human lung tumors; metastases; arachidonic acid metabolism; biosynthesis of 12-and 15-hydrox-yeicosatetraenic acids

The paper presents a retrospective evaluation of patients diagnosed with neuroendocrine tumors (NETs) from 1990 up to the present time. The cancer registry makes possible to both carry out the multilateral analyses of the end results of the treatment and realize the following up of those patients. Data regarding 756patients were analyzed. Within the study period the incidence rate of NETs patients gradually increased: 1980-1999 year - 86 patients, 2013 - 91, 2014 - 99 cases. The considerable part of the patients - 62.7% was presented by the residence from Moscow and Moscow region.

No abstract

Diagnosis and treatment of neuroendocrine carcinoma of the thymus (NECT) is the significant problem in oncology. On the clinical course these tumors are much more aggressive than epithelial tumors of the thymus. In most of observations in NECTs there is pronounced macro- and microinvasion in the mediastinal tissue and in 30% of patients there are reveled remote metastases. The study included 17 NECT patients. Surgery is the only radical method in the treatment of such patients. 17 NECT patients were operated, 3 of them were operated again due to incomplete operations in other clinics. The vast majority of patients (58.8%) at the time of visiting had advanced stage of the disease. Out of the entire group in 7 patients NECT was associated with ectopic syndrome of varying severity. According to long-term results after surgical treatment of the overall 5-year survival rate was 62.2%.